HCA Healthcare: A Long-Term Owner's View

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it enlarging an existing pie, or creating an entirely new market?5/10

  A

  The ceiling is high, but this is about enlarging an existing mature pie, not creating a new market. That needs to be clear upfront, because it directly determines where HCA sits in the Baillie Gifford ten-year five-bagger framework: steady expansion, not an explosive new species.

  Start with the size of the market. U.S. inpatient and acute-care hospitals form a huge, demand-resilient, but moderately growing mature pool. The report cites the CMS framework: hospital spending is expected to remain around 31% of total U.S. health expenditure during 2023–2033, and hospital spending is expected to grow at about 5.4% annually during 2026–2033. At the same time, the population aged 65 and above grew 3.1% in 2023–2024, reaching 61.2 million. In other words, aging provides a certain but gradual demand slope. It is HCA's natural tailwind, but it will not turn the industry into a high-growth track. Third-party estimates of the overall U.S. hospital services market land in the same range: Grand View Research estimates the 2024 U.S. hospital market at about $1.45 trillion, with a CAGR of about 5.2% through 2030, broadly consistent with the report's framework.

  Then look at HCA's position in this pie. It is growing its share of an existing pie, not opening a frontier. Based on 2025 revenue of $75.6 billion, HCA has only a single-digit percentage share of an approximately $1.4 trillion U.S. hospital market. The industry is highly fragmented, with many nonprofit and local systems. The report is clear that HCA's playbook is regional network density: by the end of 2025, it operated 190 hospitals (179 general acute-care, 7 behavioral health, and 4 rehabilitation), 121 freestanding ambulatory surgery centers, and 31 freestanding endoscopy centers, across 19 states and England. Growth comes from continuing to densify networks and capture local share in selected high-growth states, with Florida and Texas contributing about 51% of revenue and 59% of admissions, rather than inventing a new type of medical demand.

  It is indeed migrating existing demand, but that remains a redistribution within the same pie. The report notes that some care is moving from inpatient settings to ASCs, urgent care, home health, and digital workflows. HCA uses its own ASCs, freestanding emergency departments, walk-in clinics, and other non-hospital sites to capture that migration. This shifts a slice of the pie from one format to another and increases HCA's capture rate, but it does not raise the ceiling of the whole industry.

  The honest conclusion under the Baillie Gifford framework: HCA's TAM is large enough and durable enough. Medical demand will not disappear, and it should rise steadily with aging. That gives it a floor that is hard to break. But the shape of the ceiling is a mature market with gradual growth. There is no blue-sky imagination of first creating something from zero and then scaling it without limit. HCA is taking more and more of a large existing pie. That is fundamentally different, in growth ceiling terms, from a company defining a new market from scratch. Q1 dimension: credible share expansion, no market creation.

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Is growth driven mainly by volume, price, or new businesses?3/10

  A

  It most likely cannot double in five years. That is the honest answer, and it should not be inflated to fit a Baillie Gifford growth narrative. Doubling in five years requires about 15% annualized revenue growth. HCA's actual growth structure is mid-single-digit volume plus mid-single-digit price, adding up to a stable level around 7%. The gap is a matter of magnitude, not a small deviation.

  Use primary data first to calibrate the growth structure. In 2025, HCA had revenue of $75.6 billion, up 7.1% year over year, from $70.6 billion in 2024. The report breaks that down into 2.9% growth in equivalent admissions plus 4.0% growth in revenue per equivalent admission. In Q1 2026, same-facility revenue grew another 4.5%, including 3.1% growth in same-facility revenue per equivalent admission. Over a longer window, the report shows revenue rising from $58.752 billion in 2021 to $75.6 billion in 2025, a CAGR of about 6.5%. This is a very solid but moderate curve, with no year anywhere near the slope required for a doubling.

  Extrapolating from this volume-price structure, five-year growth is roughly volume of about 2%–3% times price of about 3%–4%, adding up to around 7%. Even under an optimistic assumption of sustained 7% growth, the five-year cumulative increase would be only about 40% (1.07^5 ≈ 1.40), far from a doubling (+100%). The report's own framework also does not support a doubling: the company's 2026 revenue guidance is $76.5 billion to $80.0 billion, implying about 1%–6% year-over-year growth in 2026. That is the company's official growth expectation for the nearest year, and it already rules out the doubling case.

  Growth is driven mainly by price, then volume, with new businesses as a supplement. This matters for the Baillie Gifford framework because it means the regeneration of growth is limited. The price component comes from case-mix improvement, unit price increases, and, importantly, Medicaid state-directed and supplemental payments. The report shows about $6.2 billion of such payment revenue in 2025, up from $5.5 billion in 2024. A third party also confirms that HCA attributed about half of the increase in same-facility revenue per equivalent admission to higher supplemental payments. This means a substantial part of the price growth depends on policy-driven, reversible exogenous items, not pure internal pricing power. If these programs roll back, the price engine slows. The volume component comes from bed expansion, non-hospital site expansion, and population inflow in high-growth states. It is real, but slow and highly capital-intensive. The report notes 2026 capital expenditure guidance of $5.0–$5.5 billion and about $8.8 billion of remaining completion costs for projects under construction over the next five years. New businesses, such as ASCs, urgent care, and home health, are extensions of the network rather than an independent high-speed second engine.

  The honest Baillie Gifford judgment: HCA's revenue growth is high quality, predictable, and resilient, but its speed does not support a five-year doubling. Its growth also includes a reversible policy-driven price component. Q2 dimension: intrinsic ability to double revenue, clearly absent.

  Jun 11, 2026
• QFive years from now, what will take over as the next growth engine? Does this second curve exist today?4/10

  A

  HCA does not currently have a second curve comparable in scale to its core hospital business. What it has are several tributaries extending the core curve: outpatient and non-hospital networks, plus efficiency and documentation AI. They can prolong the life of the main curve and improve its structure, but they do not form a new independent growth pole that can take over. This is a negative point in the Baillie Gifford framework: a ten-year five-bagger usually needs the second engine to be already firing as the main business matures, while HCA's engine is still essentially the same one.

  First, consider the existing extensions. The report describes HCA as operating 121 freestanding ambulatory surgery centers and 31 freestanding endoscopy centers outside its hospital network, plus ASCs, freestanding emergency departments, urgent care, walk-in clinics, and other non-hospital sites. The logic is to use its own network to capture the share of care migrating from inpatient settings to outpatient and lower-cost settings. This is a real and correct defensive layout, and HCA's outpatient expansion is reshaping its care network. But it serves the same patients, the same payment system, and the same local network. It is a format migration of the main curve, not a second curve with a new market, new customers, or new unit economics. It can keep the core business from being disrupted, but it is unlikely to lift the overall growth rate to a new level.

  Then consider the efficiency-side quasi-engine. The report says management is deploying ambient speech documentation tools to reduce documentation burden, and notes that large-scale case, process, and quality data can support operational improvement and AI documentation deployment. The value of this line is real, but it works on costs and margins, not on a second revenue curve. It makes existing revenue more profitable; it does not generate a new revenue pool on its own. Treating it as a second growth engine would overstate it.

  So what is the real next engine? Honestly, it remains the continuation of the same set of forces behind the core curve over the next ten years: natural growth in inpatient demand from aging, with the report noting that the population aged 65 and above grew 3.1% in 2023–2024 to 61.2 million and that hospital spending is expected to grow about 5.4% annually during 2026–2033; continued network densification and share gains in high-growth states such as Florida and Texas; and retaining the migrating care share through owned non-hospital assets. Together, these support a slow extension of the main curve, not an accelerating handoff to a second curve.

  The key Baillie Gifford question is: what takes over five years from now, and does that second curve exist today? The honest answer: there is no independent second curve today that can take over, has meaningful scale, and has different unit economics. There are several tributaries that extend the life of the main curve. This means HCA's growth source ten years from now is still likely to be the same engine running longer, rather than a new engine running faster. For a framework searching for a great ten-year five-bagger growth stock, this is the ceiling on HCA's growth imagination. Q3 dimension: independent second curve, largely missing.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  HCA's core competitive advantage is a compound moat of scale, local network density, operating execution, compliance and quality experience, and talent development. Over the next three to five years, I judge it as broadly stable, with modest local widening, but not unconditionally widening. This is a real operating moat, but part of its width depends on the external environment not deteriorating. Its purity is lower than that of an almost self-evidently ultra-wide moat, such as an exchange or a top consumer brand.

  Start with where it is strong and verifiable. Scale is the hardest item: the report says HCA operated 190 hospitals, 121 freestanding ambulatory surgery centers, and 31 freestanding endoscopy centers across 19 states by the end of 2025. With 2025 revenue of $75.6 billion, it sits in the largest tier among publicly comparable peers. Tenet had about $21.3 billion of 2025 revenue, and UHS about $17.4 billion. HCA is roughly twice the combined size of the two. This size creates real cost and efficiency advantages in procurement, IT, shared back office, physician development, and payer negotiation. Operating and quality execution is also documented: the report cites the Proxy as showing that more than 75% of HCA hospitals were at or above the national average in sepsis bundle compliance, and 44 hospitals were in Healthgrades' 2026 America's 250 Best Hospitals. These are operating moats, not brand mythology. Their value lies in being hard for new entrants to replicate quickly.

  But its boundaries need to be stated honestly. In the report's own moat assessment, network effects are weak: patients do not become more eager to use HCA because others use HCA. Brand is medium: it depends on local hospital and physician reputation, not a national consumer brand. Switching costs are medium: there is real friction, but not software-like lock-in. The truly strong elements are scale and culture/operating capability; the moderately strong elements are cost, channel closure, and licensing/regulatory barriers. In other words, the source of this moat is consistently doing difficult things well, not natural monopoly.

  The logic for widening over the next three to five years is this: the larger the scale, the more replicable hospital operations, supply chain, payer negotiation, physician development, IT, and quality processes become, and the lower unit costs can be. HCA's continued investment in clinical quality and documentation efficiency, such as ambient speech documentation, should further widen the operating gap versus small and mid-sized systems. Network densification in high-growth states such as Florida and Texas should strengthen local referral-loop density. All of this points to modest local widening of the moat.

  But the conditions under which it could narrow also need to be stated. This is exactly the vulnerability the report repeatedly emphasizes: HCA's profit does not come only from innate barriers. It also depends on the payment environment not deteriorating too much, case mix not worsening materially, state supplemental payments continuing to exist, about $6.2 billion in 2025 and a reversible policy item, and labor costs not staying out of control. If these reverse, the moat narrows. ACA enhanced subsidies expired at the end of 2025, and CMS is tightening the policy path for Medicaid state-directed payments, creating real exogenous pressure on moat width.

  Baillie Gifford judgment: the moat is real, verifiable, and directionally modestly widening. This is HCA's most solid attribute. But it is an execution-based moat that partly depends on the policy environment, so its purity and certainty fall short of top monopoly-like assets. Q4 dimension: strong moat, slightly widening direction, but with reversible exogenous exposure; upper-middle, not full marks.

  Jun 11, 2026
• QIf its core business is disrupted, does it have the DNA to reinvent itself? How does it treat mistakes and bad news?5/10

  A

  HCA's reinvention DNA is medium. It has real ability to adapt to gradual erosion of the core business, such as the migration of care to outpatient and lower-cost settings, but it is not a highly plastic company that can be reborn with a different life after the core is completely disrupted. This is constrained by its physical nature as a heavy-asset, heavily regulated business tied to local licenses. Under the Baillie Gifford framework, the portrait is: able to withstand slow change, weak against qualitative rupture.

  First, look at its reinvention moves when facing chronic erosion of the core. This part is positive. The largest long-term structural change described in the report is the migration of some care from inpatient/acute-care hospitals to ASCs, urgent care, home health, and digital workflows. HCA's response is not to defend inpatient beds passively, but to use its own non-hospital assets to capture the migration: by the end of 2025, it operated 121 freestanding ambulatory surgery centers, 31 freestanding endoscopy centers, plus ASCs, freestanding emergency departments, urgent care, walk-in clinics, and other sites. HCA's outpatient expansion is reshaping its care network. It is also using AI documentation tools such as ambient speech documentation to reshape internal processes. This shows that it will not be swallowed by migration; it uses the network to capture the migration, and it has the ability to adjust to known trends.

  But the physical ceiling on reinvention must be marked honestly. HCA's core assets are hospitals, land, equipment, local licenses, and payer relationships. This is a classic heavy-asset, heavily regulated, long-cycle business. The report notes 2026 capital expenditure guidance of $5.0–$5.5 billion and about $8.8 billion of remaining completion costs for projects under construction over the next five years. Such assets cannot pivot like a software company. If a disruptive technology truly emerged, for example a medical paradigm that eliminates a large amount of inpatient demand, HCA could not quickly redeploy its hospital network into something else. Its reinvention can only be migration and optimization within the existing form, not a wholesale rebirth. Fortunately, the report also judges that the true major risks are not technology eliminating hospitals, but changes in reimbursement rules, a rising uninsured share, labor supply constraints, and payer price pressure. These are slow variables that give HCA a longer adjustment window, reducing the probability that complete reinvention is required, but they do not increase its capacity for complete reinvention.

  Then consider the Baillie Gifford focus on how it treats mistakes and bad news. Observable evidence is relatively positive: management's annual bonus includes a 20% weighting for quality/patient experience metrics, long-term incentives include PSU targets based on three-year cumulative EPS, and the report cites the Proxy as showing ongoing disclosure and benchmarking against the national average for quality indicators such as sepsis bundle compliance and Healthgrades rankings. This signals a culture of facing operating shortcomings and using metrics to drive improvement. Financially, HCA also does not avoid bad news: the report notes that Ernst & Young identified estimates for contractual adjustments and implicit price concessions in revenue, and professional liability claims reserves, as key audit matters. The company records them, and operating cash flow and free cash flow have not diverged materially in recent years. There is no red flag of dressing up reimbursement estimates. This suggests that it treats accounting estimates and quality issues relatively honestly, rather than reporting only good news.

  Baillie Gifford judgment: HCA has healthy DNA in actively migrating in response to chronic erosion and using metrics to face operating/quality shortcomings. It is relatively candid about mistakes and bad news. But because of heavy-asset and heavily regulated physical constraints, it lacks the high plasticity to create a new life if the core is disrupted by a qualitative shift. Q5 dimension: reinvention, medium; enough for slow change, insufficient for qualitative rupture.

  Jun 11, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profit for five to ten years out?6/10

  A

  Management is basically trustworthy and has an unusually long-term shareholder anchor, but a discount is needed. The governance structure has real founding-family alignment, which supports long-term thinking, while the incentive design leans toward EPS and buybacks, which can encourage share shrinkage and does not necessarily mean creating per-share intrinsic value at the right price. This is the two-sided nature of HCA on Baillie Gifford's dimension of founder-like long-term alignment and willingness to sacrifice the present for five to ten years out.

  Start with the strong side: the founding family's super-long-term alignment is real and meaningful. The report says Chairman Thomas F. Frist III is a member of the founding family, and the board discloses that Frist-family-related entities collectively hold about 32% of the company. The Frist family, including the two founder generations Frist Sr./Jr., has long been HCA's core shareholder and controlling force. This combination of professional managers plus a super-long-term family shareholder matters to long-term shareholders: it naturally lengthens the decision horizon and makes the company less likely to sacrifice long-term assets for quarterly numbers. CEO Sam Hazen has served since 2019 and had long held operating and financial executive roles inside HCA before that. He is a typical internally developed chief executive, with deep understanding of, and fit with, this difficult execution-driven business.

  The incentive design also has merit. The report cites the Proxy: about 93% of the CEO's 2025 total direct compensation was performance-based, and the average for other NEOs was about 84%. Annual bonus was 80% tied to EBITDA and 20% tied to quality/patient experience. Long-term equity incentives were 50% four-year SARs and 50% PSUs tied to three-year cumulative EPS targets. There are also minimum executive shareholding requirements, and each NEO was well above the requirement by the end of 2025. This shows management is not focused only on short-term GAAP profit, and that its own interests are deeply tied to the share price.

  But the discount needs to be explained honestly. This is exactly where the report repeatedly reserves judgment. EPS has a high weight in incentives, and HCA strongly favors buybacks. The combination naturally encourages share count reduction and higher per-share metrics, which does not always equal creating per-share intrinsic value at attractive prices. The data are telling: in 2025 HCA repurchased $10.067 billion of stock, or 26.739 million shares; in 2024 it repurchased $6.042 billion, or 17.798 million shares. The report says that in Q4 2025 alone it repurchased 5.432 million shares for $2.558 billion, at an average price of about $471 per share, clearly above the current share price of about $373. The timing lacks extremely strong contrarian price discipline. More importantly, buybacks came alongside rising leverage: the report shows total debt rising from about $43.031 billion at the end of 2024 to $46.492 billion at the end of 2025, and further to $48.023 billion in Q1 2026, while the company still maintained large-scale buybacks. For long-term shareholders, this increases fragility.

  So is it willing to sacrifice current profit for five to ten years out? Partly. HCA's sustained heavy capital spending, with 2026 guidance of $5.0–$5.5 billion and about $8.8 billion of remaining construction costs over five years, shows that it is indeed investing in future network capacity and is not reluctant to spend current cash. But in capital allocation discipline, it looks more like a company that prioritizes returning cash to shareholders, and not always at cheap prices, rather than one displaying the restraint to avoid chasing prices for long-term value in a countercyclical way.

  Baillie Gifford judgment: the Frist family's 32% holding is a rare long-term anchor. Management is capable, shareholder-aware, and willing to invest in capacity. But EPS-heavy incentives, aggressive buybacks, and buybacks alongside rising leverage prevent a clean label of excellent capital allocation for now. Q6 dimension: strong founder-family alignment and adequate long-term view, but discounted capital allocation discipline; overall upper-middle leaning middle.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulators?6/10

  A

  If HCA disappeared tomorrow, patients in its dense local markets would miss it greatly, because hospitals are a necessity and local replacement capacity cannot be filled quickly. But this indispensability is local-infrastructure-level, not nationally unique and irreplaceable. At the same time, its growth model does not generally harm society, but it does operate near the boundary of regulation and public payments, so its sustainability carries an explicit policy footnote. This Baillie Gifford question asks for both indispensability and social/regulatory sustainability. HCA clearly passes the first and passes the second conditionally.

  Start with indispensability. Medical demand is one of the most rigid forms of demand. The report notes that hospital networks provide comprehensive capacity for inpatient care, emergency care, surgery, imaging, diagnostics, rehabilitation, behavioral health, and more. In markets where HCA has a high local share, especially Florida and Texas, which together account for about 51% of revenue and 59% of admissions, it is often a main regional provider of acute and inpatient capacity. Emergency and inpatient care cannot be switched the way consumer products can. Therefore, if HCA disappeared in these markets, patient access would be immediately affected and local substitute capacity would be hard to fill in the short term. That is the high indispensability of hospitals as local infrastructure. But the boundary should be stated honestly: this indispensability is geographically local and can be replaced by other hospital systems over the medium to long term. It does not have the extreme social dependence of being the only nationwide source of supply. Patients need a good hospital near home; it does not necessarily have to be HCA.

  Then consider the second layer that Baillie Gifford really presses: whether the growth model is sustainable and does not depend on harming society or regulators. This needs to be split into two sides.

  Positive side: HCA's core growth comes from meeting real medical demand, namely volume growth, plus improving clinical quality and case mix, namely price growth, while continuing to invest in quality. The report cites the Proxy: more than 75% of hospitals were at or above the national average in sepsis bundle compliance, and 44 hospitals entered Healthgrades' 2026 America's 250 Best Hospitals. Running hospitals better and serving a larger aging population is socially valuable growth in itself, not profit extracted by harming users.

  The side needing a footnote: HCA's profitability and growth depend heavily on public payment rules and state supplemental payments, making regulatory sustainability the most fragile part of its growth story. The report shows a high share of government-related programs in 2025 admissions: Medicare 19% + Managed Medicare 27% + Medicaid 4% + Managed Medicaid 11%. By inpatient revenue structure, government-related programs together account for about 57%. Revenue from Medicaid state-directed/supplemental payment programs was about $6.2 billion in 2025, up from $5.5 billion in 2024. This revenue is granted by policy and can also be withdrawn by policy. The Trump administration has proposed tightening Medicaid state-directed payments, and CMS is also setting new limits for these payments. Together with ACA enhanced subsidies expiring at the end of 2025, potentially raising uninsured levels and bad debt, HCA's growth sustainability is indeed tied to the goodwill of public policy. That is the key difference between it and a business that is fully self-sufficient and does not rely on regulatory favor. To be fair, dependence on public payments does not equal social harm. Hospitals serving Medicare/Medicaid patients are performing a social function. The risk lies in changes in policy definitions, not in growth built on damage.

  Baillie Gifford judgment: local indispensability is high, and growth serves real social demand, so the first layer is met. But the growth model is highly dependent on public payments and regulation, so sustainability carries a policy footnote, making the second layer qualified. Q7 dimension: customers would miss it and social value is positive, but regulatory sustainability is a sword overhead; upper-middle, discounted for policy exposure.

  Jun 11, 2026
• QWhat are the unit economics of this business, including gross margin and incremental returns? Do they improve or worsen as scale increases? Where does the money it earns go?5/10

  A

  HCA's unit economics are real cash, with excellent cash conversion, but they belong to a capital-intensive model with medium incremental returns. This is not a software business where scale rises, marginal cost approaches zero, and incremental returns surge. It is a heavy-asset model where scale creates stable cost and efficiency advantages, margins are moderate, and each new dollar of revenue first requires capital investment. The money it earns mainly goes to three places: capital expenditures, buybacks, and debt service. This Baillie Gifford question asks about unit economics and incremental returns. HCA's answer is high quality, but structurally heavy and capped.

  First, correct the framework: HCA should not be assessed by gross margin. The report makes clear that hospital service financials do not use gross margin as the core metric. Adjusted EBITDA margin, net margin, and operating/free cash flow are more appropriate. According to the report, 2025 revenue was $75.6 billion, Adjusted EBITDA was $15.566 billion, and the EBITDA margin was 20.6%. During 2021–2025, the EBITDA margin fluctuated narrowly between 19.6% and 21.5%. This is a business with stable but not high margins. The cost structure is heavy: in 2025, salaries and benefits were 43.5% of revenue, supplies 15.0%, other operating expenses 21.0%, depreciation and amortization 4.6%, and interest 3.0%. This is a typical high-fixed-cost, labor-intensive model.

  But there is one real bright spot in the unit economics: periodic pricing outpacing costs. The report shows that 2025 same-facility revenue per equivalent admission grew 4.1%, while salaries and benefits per equivalent admission grew only 2.4% and supplies per equivalent admission grew 2.7%. Unit price and case-mix improvement ran faster than major costs, and Q1 2026 showed a similar trend. This suggests that HCA has some ability to pass through inflation in favorable periods, and that scale and bargaining position allow unit economics to expand modestly in good conditions. But again, a substantial proportion of this unit price improvement came from reversible Medicaid supplemental payments, about $6.2 billion in 2025 and, under the report's framework, about half of the same-facility unit-price increase. It is not pure internal pricing power and can give back if conditions reverse.

  Cash conversion is the strongest part of the unit economics, and it is cross-checked by primary data. In 2025, operating cash flow was $12.636 billion, capital expenditures were $4.944 billion, and free cash flow was $7.692 billion. The report shows that cumulative free cash flow over 2021–2025 was about 90.6% of net income attributable to HCA. In 2024 and 2025, FCF even approached or exceeded net income. For a hospital operator requiring continuous heavy capital investment, this conversion rate is quite strong. It shows that profit is real cash, not accrual buildup. The report's conservative estimate of Owner Earnings is about $8.4–$8.5 billion, or about $37 per share.

  Do economics improve or worsen as scale increases? They improve modestly, but with a ceiling. Scale creates cost and efficiency advantages in procurement, IT, shared back office, physician development, and payer negotiation. The report rates cost advantage as moderately strong and scale advantage as strong. Therefore, marginal profitability of incremental revenue is slightly better than that of smaller peers. But each new unit of inpatient or surgical capacity requires upfront investment in beds, equipment, IT, and staff. Incremental capital returns are medium, not extremely high. This is fundamentally different from the explosive incremental returns of software/platform businesses, and it is the ceiling on HCA's unit economics.

  Where does the money go? Three places, and the order deserves caution. First, capital expenditures: $4.944 billion in 2025, 2026 guidance of $5.0–$5.5 billion, and about $8.8 billion of remaining construction costs over five years. Second, buybacks: $10.067 billion in 2025 and $6.042 billion in 2024, though the average buyback price was not always cheap, with Q4 2025 at about $471 per share. Third, debt service and interest: total debt had already reached $48.023 billion in Q1 2026. The report's reservation is that large buybacks are occurring alongside rising leverage. A substantial part of the cash generated by the unit economics is consumed by high-price buybacks and debt service, and not all of it necessarily converts into per-share intrinsic value.

  Baillie Gifford judgment: unit economics have high cash quality, stable margins, and periodic ability to pass through costs, clearly stronger than cash-burning targets. But this is a heavy-asset model with capital intensity, medium incremental returns, and reversible policy components in unit price. Scale effects are modest rather than exponential, and earned cash is split among capital expenditures, high-price buybacks, and debt service. Q8 dimension: unit economics are solid and cash-generative, but structurally heavy and capped; upper-middle.

  Jun 11, 2026
• QWhat conditions must hold simultaneously for it to rise fivefold in ten years? Are those conditions realistic? What expectations are embedded in today's share price?3/10

  A

  For HCA to rise fivefold in ten years, a long list of optimistic conditions would need to hold simultaneously. My honest judgment is that this is unrealistic. It directly conflicts with the report's expected annualized returns of 4%–6% in the conservative case, 7%–9% in the neutral case, and 10%–12% in the optimistic case. A fivefold return in ten years implies about 17.5% annualized total return (1.175^10 ≈ 5), far above the top of the report's optimistic scenario. Today's share price embeds steady mid-single-digit growth plus continued buyback-driven share reduction, not the explosive value creation required for a fivefold return.

  Break down the conditions needed for a ten-year fivefold return and score their realism one by one:

  First, revenue growth must accelerate materially from the current approximately 7% rate and sustain that for ten years. But HCA is a share gainer in a mature industry. The report cites the CMS framework that industry hospital spending is expected to grow only about 5.4% annually during 2026–2033. The company had 2025 revenue growth of 7.1%, and 2026 revenue guidance of $76.5–$80.0 billion, or about 1%–6% year-over-year growth. Even a long-term doubling of revenue is difficult, as discussed in Q2. A fivefold return driven by revenue is unrealistic.

  Second, margins must expand persistently rather than remain stable. But during 2021–2025, the Adjusted EBITDA margin stayed in a narrow 19.6%–21.5% range, and the cost structure is extremely heavy, with salaries and benefits at 43.5% of revenue. There is little room for large expansion.

  Third, valuation multiples must rise sharply. But HCA's current TTM PE is about 12.8x, already a reasonable range for a high-quality leader with a policy-risk discount. Relying on multiple expansion to contribute a large part of a fivefold return would require the market to re-rate it as a high-growth stock, which does not fit its mature, capital-intensive nature.

  Fourth, buybacks must keep reducing share count over the long term, at cheap prices, without leverage getting out of control. The report shows diluted shares fell from 328.75 million in 2021 to 239.5 million in 2025, a decline of about 27% over five years, which has been an important EPS driver. But buybacks coincided with total debt rising to $48.023 billion in Q1 2026, and the average buyback price was not always cheap, with Q4 2025 at about $471 per share. Relying on buybacks to contribute more than another doubling while leverage does not break becomes harder each year.

  Fifth, the policy and payment environment must not deteriorate for ten years. But about $6.2 billion of Medicaid supplemental payments in 2025 is reversible, ACA enhanced subsidies have expired, and CMS/the federal government is proposing to tighten state-directed payments. This is the least controllable exogenous variable in the fivefold story.

  The probability that all five conditions hold simultaneously for ten years is low. If any one condition fails, the fivefold outcome fails. At least three of them, revenue acceleration, multiple expansion, and no policy deterioration, conflict with current fundamentals and the environment.

  So what expectations are embedded in today's share price? At the current approximately $373 per share, with a market capitalization of about $8.28 billion scale (about $82.8 billion) and TTM PE of about 12.8x, the market embeds a fairly restrained expectation: steady mid-single-digit revenue/cash-flow growth, continued buyback-driven share reduction, and a discount for policy risk. The report's valuation conclusion confirms this: conservative Owner Earnings of about $8.4–$8.5 billion, the market assigning about 10.6x conservative OE or about 11.6x FCF, and the report's reasonable intrinsic value range of $400–$500 per share, with the current price at the top of the conservative range and the bottom of the reasonable range. In other words, the share price is not over-discounting a blue-sky fivefold narrative, nor is it stretched; it prices a good company at an acceptable but not cheap price, not a great growth stock that can rise fivefold in ten years.

  Baillie Gifford judgment, and this is the question where HCA should be marked down most in the whole framework: the many optimistic conditions required for a ten-year fivefold return cannot hold simultaneously, and the report's own optimistic return ceiling of 10%–12% is clearly below the fivefold threshold. Today's share price embeds steady growth, not explosive expectations. Q9 dimension: realism of a ten-year fivefold return is low; the price is not stretched, but the growth ceiling caps upside.

  Jun 11, 2026
• QWhy has the market not realized all this yet? Does it fail to understand, look down on it, or fail to look far enough? What could become the narrative inflection point?3/10

  A

  For HCA, this Baillie Gifford question should be answered honestly in reverse: the market actually sees it quite clearly and has not systematically misread it. HCA is not an underappreciated hidden gem. It is a high-quality leader that is reasonably priced, even with a modest policy discount. So the premise that the market has not realized this largely does not apply to HCA. What exists is a limited perception gap, leaning toward not looking far enough, rather than a major mispricing caused by failure to understand or disdain.

  Start with why failure to understand or disdain basically does not hold. HCA is a well-covered large-cap public company. The report shows its current TTM PE at about 12.8x and market capitalization at about $82.8 billion, with dense sell-side coverage: about 25 analysts currently cover it, the consensus rating is Buy, and the average target price is about $506. The market clearly knows its strengths, including scale, network density, and cash-flow quality, and it also clearly knows its weaknesses, including high leverage, high regulatory sensitivity, and aggressive buybacks. Its valuation premium over UHS (PE about 6.6x) and Tenet (PE about 9.0x) shows exactly that the market is already paying for its better scale and certainty. That is not disdain; it is recognition with a premium.

  Where is the limited not-looking-far-enough perception gap? There are two layers, and they point in opposite directions, so they should be separated. First, in the underestimation direction: the market may underestimate the durability of HCA's cash flow and the long-term compounding from buyback-driven share reduction. The report shows 2025 free cash flow of $7.692 billion, a current earnings yield of about 7.4%, and a free cash flow yield of about 8.6%, all above the 10-year Treasury yield of about 4.57% and AAA USD corporate bond yield of about 5.08% under the report's snapshot. The starting equity yield is genuinely attractive. Second, in the overestimation/justified-discount direction, and more importantly: the market is directionally right, and may even be insufficiently cautious, in discounting Medicaid supplemental payments, about $6.2 billion in 2025 and reversible, uninsured pressure after ACA subsidies expire, and high leverage, with total debt reaching $48.023 billion in Q1 2026. This means what the market has not realized may not be that HCA is worth more, but that the policy tail risk is larger. Honestly, HCA's perception gap is mild and two-sided. There is no Baillie Gifford-style opportunity where the market collectively fails to understand it and has mispriced it enough for a fivefold outcome.

  This also explains the stock's performance over the past year. HCA fell about 24% over the past 12 months, because the market has been pricing policy and supplemental-payment uncertainty, and demand-structure risk from ACA subsidy expiration, into the share price in real time. This is the market recognizing risk, not the market failing to recognize value.

  So what could become the narrative inflection point? For HCA, inflection points are two-sided and highly tied to exogenous policy and fundamental turns, not to a neglected intrinsic value suddenly being discovered:

  Upside narrative inflection points: uncertainty around Medicaid state-directed/supplemental payments resolves more mildly than the market fears, while CMS is currently tightening and the policy path remains unsettled; the uninsured/bad-debt impact after ACA subsidies expire proves manageable; same-facility revenue per equivalent admission continues to outpace labor and supply costs, one of the report's most important fragile assumptions; and valuation multiples recover from the policy discount.

  Downside narrative inflection points: a sharp decline in supplemental payments, net debt/EBITDA staying above 3.5x for a long time while aggressive buybacks continue, uninsured rates and bad debt rising again, or a major quality/litigation event. The report is clear that these would reprice HCA from a high-quality cash cow into a high-leverage policy stock.

  Baillie Gifford judgment: HCA does not fit the image of a dusty growth stock the market fails to understand or looks down on. It is a high-quality leader that is reasonably priced with a modest policy discount. The perception gap is small and two-sided, and narrative inflection depends on external policy resolution rather than discovery of intrinsic value. Q10 dimension: perception gap is limited and directionally neutral to slightly negative, not a mispricing opportunity capable of supporting a fivefold outcome.

  Jun 11, 2026